Buy Tecentriq (atezolizumab)
€3,604.50
Tecentriq (atezolizumab) is a medicine used to treat locally advanced or metastatic urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) and advanced triple-negative breast cancer (TNBC).
Tecentriq (atezolizumab)Â is a programmed cell death ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with the following conditions:
- Locally advanced or metastatic urothelial carcinoma where the disease either progresses during or after platinum-based chemotherapy, or occurs within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy, or which is not suitable for cisplatin chemotherapy.
- metastatic non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy.
- plus Nab-Paclitaxel (chemotherapy) for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors exhibit PD-L1 expression.
How does Tecentriq (atezolizumab) work?
Tecentriq (atezolizumab) belongs to a class of immunotherapeutic drugs known as checkpoint inhibitors.
The drug prevents a protein called PD-L1, found on some tumor cells, from binding to another protein, PD-1, on immune cells. The binding of these “checkpoint” proteins suppresses the immune response. Tecentriq (atezolizumab) is a monoclonal antibody that binds to PD-L1 and blocks its interaction with the PD-1 and B7.1 receptors. By blocking this interaction, checkpoint inhibitors “release the brakes” on the immune system, allowing immune cells to attack tumors.
Is Tecentriq (atezolizumab) approved?
Tecentriq (atezolizumab) has been approved by:
- Food and Drug Administration (FDA) (USA)
- On May 18, 2016, the FDA approved Tecentriq (atezolizumab) for locally advanced or metastatic urothelial carcinoma with disease progression during or after prior chemotherapy. On April 17, 2017, the FDA expanded the approval to include the use of Tecentriq (atezolizumab) as a first-line treatment for advanced or metastatic urothelial carcinoma in patients ineligible for cisplatin-based chemotherapy.
- on October 18, 2016 for metastatic non-small cell lung cancer (NSCLC).
- Health Canada am 12. April 2017
- in locally advanced or metastatic urothelial carcinoma, with disease progression during or after prior chemotherapy.
- for first-line treatment of adult patients with advanced small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide.
- For first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) without squamous cell carcinoma in combination with bevacizumab, paclitaxel and carboplatin.
- for adult patients with locally advanced or metastatic NSCLC with progression during or after platinum-based chemotherapy.
- Therapeutic Goods Administration (TGA) (AUS)
- on July 27, 2017 for metastatic non-small cell lung cancer (NSCLC).
- European Medicines Agency (EMA) (EU)
- on 22 September 2017 for locally advanced or metastatic non-small cell lung cancer (NSCLC) and metastatic urothelial carcinoma (mUC) in patients who have previously been treated with platinum-based chemotherapy, and as a first-line treatment for advanced or metastatic urothelial carcinoma in patients for whom cisplatin chemotherapy is not an option.
- on August 29, 2019 in combination with nab-paclitaxel for advanced TNBC in patients who had not previously received chemotherapy for metastatic disease.
- Medsafe on February 14, 2019
- for first-line treatment of patients with metastatic non-squamous NSCLC who do not have genomic tumor EGFR or ALK aberrations.
- for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.
- for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) without squamous cell carcinoma.
- for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.
How do I take Tecentriq (atezolizumab)?
Detailed information on the dosage and administration of Tecentriq (atezolizumab) can be found in the ” References ” section.
The recommended therapy consists of:
- 1200 mg as an intravenous infusion over 60 minutes every 3 weeks.
- Dilute before intravenous infusion.
| Quantity |
1 vial of 20 mL |
|---|
Shipping and delivery
All orders will only be shipped after payment confirmation. Please enter your shipping details and select the payment method that suits you best.
Shipping costs:
You should always be clearly informed about the total price of your purchase, including delivery and any other associated costs.
You must explicitly agree to any additional charges, for example, if the retailer offers express shipping or gift wrapping.
Damaged Goods:
The retailer is responsible for all damage to the product, from shipping to receipt.
If you have purchased an item that does not match the advertised product in appearance or function, you have the right to request a repair, a replacement, or, if neither of these is possible, a refund.
- Non-delivery:
If you have not received the product within 30 days or by the agreed date, you must notify the seller and grant them a reasonable extension of the delivery period.
For example, if the seller informs you of a one-week delay due to problems with their suppliers, it seems reasonable to grant them this additional week. If, despite the extension, the seller still fails to fulfill their obligation to deliver, you have the right to withdraw from the contract and receive an immediate refund.
Related products
Buy Darzalex (Daratumumab)
Who is Darzalex (daratumumab) suitable for?
Darzalex (daratumumab) is indicated for patients with:-
Newly diagnosed multiple myeloma for which autologous stem cell transplantation is not an option (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.
-
Patients with multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone.
-
Patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (third-line therapy). For this indication, it is used in combination with pomalidomide and dexamethasone.
-
Multiple myeloma patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are doubly refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.
Buy Ibrance (Palbociclib)
What is Ibrance (palbociclib) for?
Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (hormone therapy) as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression after endocrine therapy.How does Ibrance (palbociclib) work?
Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
Before a cell can divide, it must go through four phases. The first phase is a growth phase (G1 phase), the second a synthesis phase (S phase), the third another growth phase (G2 phase), and the final phase, in which the cell divides (M phase). Cancer cells divide extremely rapidly and pass through these four phases quickly. Palbociclib blocks the transition from the first G1 phase to the second S phase. This occurs by inhibiting cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) – two proteins involved in entering the S phase [1] .
Buy Kadcyla (Trastuzumab Emtansine)
Buy Keytruda (Pembrolizumab)
Buy Opdivo (Nivolumab)
What is Opdivo (nivolumab) for?
Opdivo (nivolumab) is indicated for the treatment of patients with the following conditions:- metastatic melanoma as monotherapy or in combination with ipilimumab
- metastatic non-small cell lung cancer (NSCLC) whose cancer has progressed during or after chemotherapy
- advanced renal cell carcinoma who have previously received anti-angiogenic therapy
- classical Hodgkin lymphoma that has relapsed or progressed after other treatments
- Recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) with disease progression during or within 6 months of receiving platinum-based chemotherapy
- locally advanced, unresectable or metastatic urothelial carcinoma after progression under platinum-based therapy
- Metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) that has progressed after treatment with a fluoropyrimidine, oxaliplatin and irinotecan
- hepatocellular carcinoma in patients previously treated with sorafenib
- for the adjuvant treatment of completely resected esophageal cancer or cancer of the gastroesophageal junction (GEJ) with persistent pathological residual disease in patients who have received neoadjuvant radiochemotherapy (CRT).
Buy Perjeta (Pertuzumab)
What is Perjeta (pertuzumab) for?
Perjeta (pertuzumab) is indicated for the treatment of HER2-positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory or early breast cancer as part of a complete early breast cancer treatment regimen.
Reviews
There are no reviews yet.